The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Key Inclusion Criteria:

• Males of any race, between 18 and 65 years of age, inclusive.
• Male participants in good health as determined by past medical history, physical examination, vital signs, ECG and laboratory tests at screening
• Must have a body mass index (BMI) between 18 and 32 kg/m^2

Key Exclusion Criteria:

• Participants with a clinically relevant history or presence of any clinically significant disease
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed)
• History of drug or alcohol abuse within 1 year prior to check-in
• Use or intended use of any nonprescription medications/products including vitamins, minerals, herbal/plant-derived preparations within 7 days prior to check-in
• A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result and/or a positive human immunodeficiency virus (HIV) at screening
• Use of tobacco- or nicotine-containing products within 3 months prior to check-in
• Use or intended use of any prescription medications/products within 14 days prior to check-in

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.